{
    "organizations": [],
    "uuid": "c0afef92db8cddf012b296b5653affc82079817b",
    "author": "",
    "url": "https://www.reuters.com/article/brief-pfizer-provides-update-on-proposed/brief-pfizer-provides-update-on-proposed-trastuzumab-biosimilar-idUSASC09WRN",
    "ord_in_thread": 0,
    "title": "BRIEF-Pfizer Provides Update On Proposed Trastuzumab Biosimilar",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 23, 2018 / 11:47 AM / Updated 13 minutes ago BRIEF-Pfizer Provides Update On Proposed Trastuzumab Biosimilar Reuters Staff April 23 (Reuters) - Pfizer Inc: * PFIZER PROVIDES UPDATE ON PROPOSED TRASTUZUMAB BIOSIMILAR * PFIZER INC - IN CRL, FDA HIGHLIGHTED NEED FOR ADDITIONAL TECHNICAL INFORMATION * PFIZER INC - RECEIVED CRL FROM UNITED STATES FDA IN RESPONSE TO BIOLOGICS LICENSE APPLICATION FOR COMPANY‘S PROPOSED TRASTUZUMAB BIOSIMILAR * PFIZER - ADDITIONAL REQUESTED INFORMATION BY FDA DOES NOT RELATE TO SAFETY OR CLINICAL DATA SUBMITTED IN BLA FOR CO‘S PROPOSED TRASTUZUMAB BIOSIMILAR * PFIZER - “WORKING CLOSELY” WITH FDA TO ADDRESS CONTENTS OF LETTER ON PROPOSED TRASTUZUMAB BIOSIMILAR Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)",
    "published": "2018-04-23T14:46:00.000+03:00",
    "crawled": "2018-04-23T15:05:27.008+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "updated",
        "minute",
        "ago",
        "provides",
        "update",
        "proposed",
        "trastuzumab",
        "biosimilar",
        "reuters",
        "staff",
        "april",
        "reuters",
        "pfizer",
        "inc",
        "pfizer",
        "provides",
        "update",
        "proposed",
        "trastuzumab",
        "biosimilar",
        "pfizer",
        "inc",
        "crl",
        "fda",
        "highlighted",
        "need",
        "additional",
        "technical",
        "information",
        "pfizer",
        "inc",
        "received",
        "crl",
        "united",
        "state",
        "fda",
        "response",
        "biologics",
        "license",
        "application",
        "company",
        "proposed",
        "trastuzumab",
        "biosimilar",
        "pfizer",
        "additional",
        "requested",
        "information",
        "fda",
        "relate",
        "safety",
        "clinical",
        "data",
        "submitted",
        "bla",
        "co",
        "proposed",
        "trastuzumab",
        "biosimilar",
        "pfizer",
        "working",
        "closely",
        "fda",
        "address",
        "content",
        "letter",
        "proposed",
        "trastuzumab",
        "biosimilar",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}